The global prothrombin complex concentrate (PCC) Market size is poised to reach USD 1,076.5 million by 2025, registering a CAGR of 9.1% during the forecast period. Rising prevalence of hemophilia across the globe is expected to be a major growth driver for this market. Hemophilia is a rare blood disorder wherein normal blood clotting does not occur due to absence or insufficient amount of clotting proteins in the individual’s blood. Though rare, the disorder has been found to have increased in prevalence. According to a study led by Canada’s McMaster University, more than 1,125,000 men worldwide suffer from this inherited affliction. PCC treatments have been found to be highly effective in managing hemophilia, a study published in JAMA Pediatrics, a peer-reviewed medical journal, found. This bodes well for the prothrombin complex concentrate market growth as adoption rate of PCC therapeutics picks up pace.
Highlights of the Prothrombin Complex Concentrate Market Report Include:
- Microscopic study of the various factors driving and restraining the market
- Careful classification and research of the market segments
- Accurate computation of market figures
- Comprehensive analysis of the regional dynamics and competitive landscape
For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/industry-reports/prothrombin-complex-concentrate-pcc-market-100102
Key Players Operating in The Prothrombin Complex Concentrate Market Include:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Sanquin
- China Biologic Products Holdings, Inc.
- Grifols SA
- Shire
- Octapharma AG
- Kedrion S.p.A
- CSL Behring
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/prothrombin-complex-concentrate-pcc-market-100102
The report focuses on global major leading industry players of market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. This report focuses on Prothrombin Complex Concentrate Market Trend, volume and value at global level, regional level and company level. From a global perspective, this report represents overall Prothrombin Complex Concentrate Market Size by analysing historical data and future prospect.
With tables and figures helping analyse worldwide Prothrombin Complex Concentrate Market Forecast provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Asia-Pacific to Boast a High CAGR; North America to Dominate
With a revenue generation of USD 210.2 million in 2017, North America is set to lead the global prothrombin complex concentrates market share in the forecast period. This is mainly owing to the presence of major players in the region. Evolving health insurance policies for rare blood disorders and increase in the number of plasma collection centres in India and China will enable Asia-Pacific to grow at an impressive CAGR till 2025. In Europe, the market will be driven by the rising prevalence of congenital coagulation factors deficiency.
Quick Buy:
https://www.fortunebusinessinsights.com/checkout-page/100102
Growing Utilization of 4-Factor PCC to Boost Sales
The 4-factor prothrombin complex concentrate (4F-PCC) is used to expedite the reversal of vitamin K antagonist (VKA). It carries several benefits which is fuelling its popularity. For example, this PCC variant contains coagulation factor VII, which is not present in other variants. Furthermore, administering 4F-PCC is relatively easy as it requires a reduced infusion volume and it also minimizes the risk of pathogen transmission. Effectivity of its treatment mechanism has surged its adoption rate and given it international recognition. For instance, the British Committee for Standards in Haematology has prescribed specific guidelines for the deployment of PCC techniques in treating haemophiliacs. These developments are expected to provide a positive thrust to the market for this medication technology.
